NASDAQ:RXRX Recursion Pharmaceuticals (RXRX) Stock Price, News & Analysis $6.49 +0.23 (+3.67%) Closing price 07/25/2025 04:00 PM EasternExtended Trading$6.51 +0.02 (+0.31%) As of 07/25/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Recursion Pharmaceuticals Stock (NASDAQ:RXRX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get RXRX alerts:Sign Up Key Stats Today's Range$5.93▼$6.5050-Day Range$4.08▼$6.5452-Week Range$3.79▼$12.36Volume23.55 million shsAverage Volume33.10 million shsMarket Capitalization$2.64 billionP/E RatioN/ADividend YieldN/APrice Target$7.00Consensus RatingHold Company Overview Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah. Read More Recursion Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks16th Percentile Overall ScoreRXRX MarketRank™: Recursion Pharmaceuticals scored higher than 16% of companies evaluated by MarketBeat, and ranked 803rd out of 939 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.2 / 5Analyst RatingHold Consensus RatingRecursion Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 2 buy ratings, 4 hold ratings, and no sell ratings.Amount of Analyst CoverageRecursion Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.Read more about Recursion Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Recursion Pharmaceuticals are expected to grow in the coming year, from ($1.57) to ($1.42) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Recursion Pharmaceuticals is -3.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Recursion Pharmaceuticals is -3.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRecursion Pharmaceuticals has a P/B Ratio of 2.49. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Recursion Pharmaceuticals' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted35.52% of the float of Recursion Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverRecursion Pharmaceuticals has a short interest ratio ("days to cover") of 4.5.Change versus previous monthShort interest in Recursion Pharmaceuticals has recently decreased by 2.22%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldRecursion Pharmaceuticals does not currently pay a dividend.Dividend GrowthRecursion Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted35.52% of the float of Recursion Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverRecursion Pharmaceuticals has a short interest ratio ("days to cover") of 4.5.Change versus previous monthShort interest in Recursion Pharmaceuticals has recently decreased by 2.22%, indicating that investor sentiment is improving. News and Social Media3.0 / 5News Sentiment0.45 News SentimentRecursion Pharmaceuticals has a news sentiment score of 0.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.06 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 12 news articles for Recursion Pharmaceuticals this week, compared to 10 articles on an average week.Search Interest78 people have searched for RXRX on MarketBeat in the last 30 days. This is an increase of 28% compared to the previous 30 days.MarketBeat Follows35 people have added Recursion Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 6% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Recursion Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 8.43% of the stock of Recursion Pharmaceuticals is held by insiders.Percentage Held by Institutions89.06% of the stock of Recursion Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Recursion Pharmaceuticals' insider trading history. Receive RXRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Recursion Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address RXRX Stock News HeadlinesHow Palantir, Tempus, Nvidia-Backed Recursion Are Disrupting Big PharmaJuly 25 at 1:53 PM | benzinga.comRecursion Pharmaceuticals (RXRX) Jumps 9.6% Ahead of Q2 EarningsJuly 22, 2025 | insidermonkey.comElon Musk: “This will transform civilization as we know it.”Robots are no longer science fiction — they’re the next trillion-dollar megatrend. According to Forbes, by 2025, robots will shift from novelty to necessity — disrupting nearly every industry in their path. But one overlooked sector could become the real winner… and one little-known company may be the best way to get ahead of the boom.July 26 at 2:00 AM | Weiss Ratings (Ad)Brokerages Set Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) PT at $7.00July 22, 2025 | americanbankingnews.comRecursion Pharmaceuticals Acquires Full Rights to REV102, Potential Oral Therapy for Rare Bone Disorder HypophosphatasiaJuly 21, 2025 | finance.yahoo.comRecursion Pharmaceuticals (RXRX) Sees 14% Price Surge Over Last MonthJuly 20, 2025 | finance.yahoo.comMorgan Stanley Assumes Coverage of Recursion Pharmaceuticals (RXRX) Stock with an Equal Weight RatingJuly 10, 2025 | msn.comRecursion Pharmaceuticals (RXRX) Rallies 8.7% on HypophosphatasiaJuly 9, 2025 | insidermonkey.comSee More Headlines RXRX Stock Analysis - Frequently Asked Questions How have RXRX shares performed this year? Recursion Pharmaceuticals' stock was trading at $6.76 at the beginning of the year. Since then, RXRX stock has decreased by 4.0% and is now trading at $6.49. How were Recursion Pharmaceuticals' earnings last quarter? Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) posted its quarterly earnings data on Monday, May, 5th. The company reported ($0.50) EPS for the quarter, missing the consensus estimate of ($0.44) by $0.06. The business's revenue was up 7.2% compared to the same quarter last year. Read the conference call transcript. When did Recursion Pharmaceuticals IPO? Recursion Pharmaceuticals (RXRX) raised $306 million in an IPO on Friday, April 16th 2021. The company issued 18,000,000 shares at a price of $16.00-$18.00 per share. Goldman Sachs, J.P. Morgan, BofA Securities, SVB Leerink, Allen & Co. and KeyBanc Capital Markets served as the underwriters for the IPO. Who are Recursion Pharmaceuticals' major shareholders? Recursion Pharmaceuticals' top institutional shareholders include SteelPeak Wealth LLC (0.02%), Blair William & Co. IL (0.02%), KLP Kapitalforvaltning AS (0.02%) and Kieckhefer Group LLC (0.01%). Insiders that own company stock include Mubadala Investment Co Pjsc, Blake Borgeson, Michael Secora, Christopher Gibson, Tina Marriott, Dean Y Li, Tina Marriott Larson, Shafique Virani, Terry-Ann Burrell and Zavain Dar. View institutional ownership trends. How do I buy shares of Recursion Pharmaceuticals? Shares of RXRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Recursion Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Recursion Pharmaceuticals investors own include NVIDIA (NVDA), Invesco QQQ (QQQ), Meta Platforms (META), Broadcom (AVGO), CrowdStrike (CRWD) and Advanced Micro Devices (AMD). Company Calendar Last Earnings5/05/2025Today7/25/2025Next Earnings (Estimated)8/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:RXRX CIK1601830 Webwww.recursion.com Phone385-269-0203Fax801-821-2872Employees400Year FoundedN/APrice Target and Rating Average Price Target for Recursion Pharmaceuticals$7.00 High Price Target$10.00 Low Price Target$5.00 Potential Upside/Downside+7.9%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)($1.77) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$463.66 million Net Margins-961.32% Pretax Margin-962.17% Return on Equity-74.70% Return on Assets-54.02% Debt Debt-to-Equity Ratio0.02 Current Ratio4.11 Quick Ratio4.11 Sales & Book Value Annual Sales$58.84 million Price / Sales44.84 Cash FlowN/A Price / Cash FlowN/A Book Value$2.61 per share Price / Book2.49Miscellaneous Outstanding Shares406,490,000Free Float372,227,000Market Cap$2.64 billion OptionableOptionable Beta0.91 Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:RXRX) was last updated on 7/26/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredTrump's 2025 Economic Revolution Is Here Are Your Retirement Savings Ready?Time is short. Trump's reforms may be coming fast—and the financial system roller coaster may be a ride that y...Create New Advertiser | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…GoldCo Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Recursion Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Recursion Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.